Showing 190 results
- https://www.novartis.com/news/novartis-entresto-indicated-treatment-hypertension-china
- https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-sabatolimab-mbg453-myelodysplastic-syndromes
- https://www.novartis.com/news/novartis-provides-update-phase-iii-stand-trial-assessing-crizanlizumab
- https://www.novartis.com/news/novartis-2022-financial-results
Novartis announces the company’s fourth quarter and 2022 full year financial results.
- https://www.novartis.com/news/novartis-expands-humanitarian-efforts-ukraine-through-donation-essential-medicines
- https://www.novartis.com/news/novartis-announces-first-european-donation-hydroxychloroquine-switzerland
- https://www.novartis.com/news/novartis-coronavirus-update-supply-chain-response-measures-efpia-rd-call
- https://www.novartis.com/news/expanding-car-t-manufacturing-australia
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. - https://www.novartis.com/news/beacon-hope-addressing-health-disparities-through-holistic-community-based-collective-action
- https://www.novartis.com/news/novartis-financial-results-q2-2021
Novartis announced the company’s financial results for the second quarter and first half of 2021.
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 19
- › Next page